title: [Multiple effect of simvastatin on vascular endothelium of hypercholesterolemia patients].
abstract: OBJECTIVE
  To observe the multiple influence of cholesterol-lowering drug (simvastatin) on ankle brachial index (ABI), flow-mediated dilation (FMD) and nitroglycerin-mediated dilation (NMD) of brachial artery blood vessel endothelium, and plasma level of monocyte chemotactic protein 1 (MCP-1) of hypercholesterolemia patients without coronary heart disease (CHD).
  
  
  METHODS
  In the study, 51 patients with hypercholesterolemia application were treated with simvastatin (20 mg/d) therapy for 12 weeks. The metabolic index, ankle brachial index (ABI), FMD of brachial artery blood vessel endothelium detected by color doppler ultrasound instrument, the NMD of artery endothelial and the level of MCP 1 were measured before and after therapy respectively. All the results were analyzed and compared with another 30 cases of hypercholesterolemia patients selected without simvastatin treatment.
  
  
  RESULTS
  After simvastatin therapy, the TC (total cholesterol) and LDL-C (low density lipoprotein cholesterin) levels were reduced apparently,the values decreased from the original (6.06 ± 1.03) mmol/L and (3.60 ± 0.82) mmol/L to (4.98 ± 1.34) mmol/L and (3.41 ± 0.10) mmol/L respectively (P<0.01, P< 0.05). Compared with no simvastatin treatment, the bilateral ABI levels were significantly elevated. The right side of ABI (ABIR) elevated from 1.11 ± 0.06 to 1.19 ± 0.07, and the left side of ABI (ABIL) also elevated from 1.12 ± 0.06 to 1.19 ± 0.10 (both sides were P<0.01). The FMD significantly increased from 7.75% ± 11.30% to 14.20% ± 15.39% (P < 0.05). The plasma levels of MCP-1 were apparently reduced from (112.0 ± 7.8) ng/L to (108.9 ± 6.2) ng/L (P < 0.05). All these items showed no obvious change within the control group.
  
  
  CONCLUSIONS
  The API, FMD and plasma levels of MCP-1 of hypercholesterolemia patients without clear coronary heart disease can be improved by simvastatin treatment.
authors.affiliation: Peking University Health Science Center Hospital, Beijing 100191, China.
authors.forename: Jing-lin
authors.initials: JL
authors.lastname: Guan
authors.affiliation: Peking University Health Science Center Hospital, Beijing 100191, China.
authors.forename: Wen
authors.initials: W
authors.lastname: Jiang
authors.affiliation: Peking University School of Basic Medical Science, Beijing 100191, China.
authors.forename: Huai-yu
authors.initials: HY
authors.lastname: Wang
authors.affiliation: Department of Cardiology, Peking Univeristy Third Hospial, Beijing 100191, China.
authors.forename: Hui
authors.initials: H
authors.lastname: Zeng
authors.affiliation: Peking University Health Science Center Hospital, Beijing 100191, China.
authors.forename: Su-min
authors.initials: SM
authors.lastname: Zhang
authors.affiliation: Department of Endocrinology, Beijing Chaoyang Hospital, Capital Medical University, Beijing, 100020, China.
authors.forename: Guang
authors.initials: G
authors.lastname: Wang
authors.affiliation: Department of Cardiology, Peking Univeristy Third Hospial, Beijing 100191, China.
authors.forename: Jie-ming
authors.initials: JM
authors.lastname: Mao
mesh_terms: D055109:Ankle Brachial Index; D000924:Anticholesteremic Agents / Q000494:pharmacology*; D001916:Brachial Artery / Q000473:pathology; D016022:Case-Control Studies; D018932:Chemokine CCL2 / Q000097:blood; D002784:Cholesterol / Q000097:blood; D003327:Coronary Disease; D004730:Endothelium, Vascular / Q000187:drug effects*; D006801:Humans; D006937:Hypercholesterolemia / Q000188:drug therapy*; D019821:Simvastatin / Q000494:pharmacology*; D014664:Vasodilation
chemical_list: D000924:Anticholesteremic Agents; C111835:CCL2 protein, human; D018932:Chemokine CCL2; D002784:Cholesterol; D019821:Simvastatin